p-Tau217 might be the Benjamin Button of biomarkers—starting off old and ending up young. Seriously, p-tau217 is unusually high at birth before waning with age, scientists report. In a cross-sectional ...

Two studies analyzed tau-PET scans from thousands of participants in dozens of cohorts. Tangle prevalence increased with age among cognitively normal people, but decreased among those with dementia.

Is Alzheimer’s disease different in people with Down’s? Two recent proteomics studies say yes. In the July 1 Nature Communications, scientists led by Erik Johnson at Emory University School of ...

The role of ApoE has been well-studied outside of the cell, but what happens after it’s let inside? Scientists led by Raimund Dutzler, University of Zurich, have identified Tweety homologue 2 as an ...

Every participant in the Dutch 100-Plus study is, by definition, exceptional. Just to qualify for enrollment, they must have remained cognitively healthy even after logging 100 laps around the sun.

In a June 12 conference at UW-Madison, researchers gathered from across the U.S. and abroad to discuss the latest progress on TDP-43 biomarkers. In all, 74 people attended in person, and 727 virtually ...

Membraneless liquid droplets called stress granules can concentrate TDP-43. Oxidation of the protein in these blobs triggers a liquid-to-solid transition. Disulfide bonds and structural changes in the ...

Signaling through the TREM2 receptor fuels an ever-growing list of known microglial functions in the brain, and gene variants that hobble TREM2 signaling beckon Alzheimer’s disease. Ergo, activating ...

As advanced biomedical technologies have allowed scientists to gather growing and increasingly complex datasets, even the most brilliant human minds grappling with the windfall can’t possibly keep up.

Over the last 40 years, age-adjusted dementia prevalence in the U.S. has dropped by two-thirds. This predicts a 25 percent rise in total dementia cases by 2050, due to population aging. The findings ...

This article discusses the role of receptors and lysosomal dysfunction in APOE variant-related Alzheimer's disease risk.

Fewer than 1 percent of amyloid-targeted monoclonal antibodies like lecanemab and donanemab reach their targets in the brain. The excess doses required to make up for this problem raise the risk of ...